ID   MEL-CLS-1
AC   CVCL_5619
SY   FO-1; FO #1; FO 1
DR   BTO; BTO:0002943
DR   cancercelllines; CVCL_5619
DR   CLS; 300175
DR   Wikidata; Q54905083
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=994214;
RX   PubMed=1898655;
RX   PubMed=2624919;
RX   PubMed=3518877;
RX   PubMed=8537970;
RX   PubMed=15661905;
CC   Population: Caucasian.
CC   Characteristics: Established from a xenograft (CLS=300175).
CC   Doubling time: 38 hours (Note=At 49th passage) (PubMed=994214).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CLS=300175).
CC   Derived from site: Metastatic; Iliac lymph node; UBERON=UBERON_0015878.
ST   Source(s): CLS
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 12
ST   D16S539: 9,12
ST   D18S51: 17
ST   D21S11: 27
ST   D3S1358: 15,18
ST   D5S818: 12,13
ST   D7S820: 9,11
ST   D8S1179: 12,14
ST   FGA: 19,23
ST   Penta D: 9
ST   Penta E: 14,17
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 17,18
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 21
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=994214; DOI=10.1093/jnci/56.6.1131;
RA   Giovanella B.C., Stehlin J.S. Jr., Santamaria C., Yim S.O.,
RA   Morgan A.C. Jr., Williams L.J. Jr., Leibovitz A., Fialkow P.J.,
RA   Mumford D.M.;
RT   "Human neoplastic and normal cells in tissue culture. I. Cell lines
RT   derived from malignant melanomas and normal melanocytes.";
RL   J. Natl. Cancer Inst. 56:1131-1142(1976).
//
RX   PubMed=1898655; DOI=10.1172/JCI114984;
RA   D'Urso C.M., Wang Z.-G., Cao Y., Tatake R.J., Zeff R.A., Ferrone S.;
RT   "Lack of HLA class I antigen expression by cultured melanoma cells
RT   FO-1 due to a defect in B2m gene expression.";
RL   J. Clin. Invest. 87:284-292(1991).
//
RX   PubMed=2624919; DOI=10.1007/BF01744892;
RA   Guarini L., Temponi M., Edwalds G.M., Vita J.R., Fisher P.B.,
RA   Ferrone S.;
RT   "In vitro differentiation and antigenic changes in human melanoma cell
RT   lines.";
RL   Cancer Immunol. Immunother. 30:262-268(1989).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=8537970; DOI=10.1093/jnci/88.2.100;
RA   Restifo N.P., Marincola F.M., Kawakami Y., Taubenberger J.K.,
RA   Yannelli J.R., Rosenberg S.A.;
RT   "Loss of functional beta 2-microglobulin in metastatic melanomas from
RT   five patients receiving immunotherapy.";
RL   J. Natl. Cancer Inst. 88:100-108(1996).
//
RX   PubMed=15661905; DOI=10.4049/jimmunol.174.3.1462;
RA   Chang C.-C., Campoli M., Restifo N.P., Wang X.-H., Ferrone S.;
RT   "Immune selection of hot-spot beta 2-microglobulin gene mutations,
RT   HLA-A2 allospecificity loss, and antigen-processing machinery
RT   component down-regulation in melanoma cells derived from recurrent
RT   metastases following immunotherapy.";
RL   J. Immunol. 174:1462-1471(2005).
//